½ðÄê»á

À´Ô´£º·¿²ú´ïÈËdlc  £¬×÷Õߣº  £¬£º

°¥  £¬à¸¸úÄ㽲࣠ £¬ÄãÏþ²»µÃ½ðË®ÇøÓиöºÜÓÐζµÀµÄµØ·½  £¬½ÐË£µÄÏï×Ó¡£Ìýµ½Õâ¸öÃû×Ö  £¬ÊDz»ÊǾ;õµÃÓеãÒâ˼£¿¸ü×ÓÄãÒªÊÇϲ»¶¹ä½Ö³Ô¹¤¾ß  £¬»¹ÏëÕÒµãËíµÀµÄ¸ÐÊÜ  £¬ßÖ¸öµØ·½¾ø¶Ô²»»áÈÃÄãʧÍû¡£ÄǾ¿¾¹½ðË®ÇøË£µÄÏï×ÓÔÚÄÄÀïÄØ£¿ÎÒ½ñÌì¾ÍÀ´¸øÄãêþ³¶êþ³¶¡£

½ðË®ÇøË£µÄÏï×Ó¾¿¾¹ÔÚÄĹÕ£¿

ÄãÒªÎÊßÖ¸öË£µÄÏï×Ó¾ßÌåÔÚÄÄ¿­  £¬à¸¸úÄ㽲࣠ £¬ÂÑÔ¶ÂÑԶûµÃ  £¬¾ÍÔÚ½ðË®ÇøµÄºàáé±ß  £¬¹Õ¸öÍä¾Íµ½ÁË¡£Ä㿪ͷµ½½ðË®ÇøÄÇÆäÖÐɽ·ËÄÖÜÕÒ  £¬ÎÊÎÊ·±ßÂôС³ÔµÄ°¢ÆÅ  £¬ËýÃDZȵ¼º½»¹×¼  £¬Ö±ÂéÖ±¾ÍÄÜ´øÄãÕÒµ½ßÖ¸öµØ·½¡£

Õû¸öÏï×Ó²»ËãÌØ±ð´ó  £¬ÈýËÄÌõÏï×Ó½»²æ×Å  £¬ÅªµÃÏñ¸öÃÔ¹¬í¥×Ó  £¬¿ÉÊÇÿÌõÏï×Ó¶¼ÓÐ·×ÆçÑùµÄζµÀ¡£½²ÕæµÄ  £¬µÚÒ»´Î¿ËÃâ²»ÁË»á¸ãÂÑÃÔ·  £¬µ«Ã»Ê  £¬Ïï×ÓÀïÈÈÄÖµÃÂÑ»ðÌÌ  £¬Ëæ±ãÒ»¸öµØ·½Í£ÏÂÀ´¶¼ÓиãÍ·¡£

Ë£µÄÏï×ÓÓÐɶºÃ³ÔµÄ£¿

ุúÄã½²  £¬½ðË®ÇøßÖ¸öË£µÄÏï×Ó  £¬¼òÖ±ÊdzԻõµÄÌìÌá£×î×ÅÃûµÄ¾ÍÊÇÄǼÒÂôÂÝòÏ·ÛµÄÆÌ×Ó  £¬Î¶µÀµð¸Ü  £¬ÂÑÊǵÄÕý×Ú  £¬³ÔÒ»¿ÚÄãÂÑ»á¾õµÃ½Åֺͷ¶¼´ò¾í£¡

ÁíÓÐÒ»¼ÒÂôÏÖ¿¾³ô¶¹¸¯µÄ  £¬Ã¿´Î¶¼ÒªÅŶӰëÌì  £¬³ôµ½ÂѶ¼·É  £¬µ«³Ô½ø×ì°ÍÄãÂѻᷢÃ÷ÏãµÃÒªÃü¡£ÅÔ±ßÁíÓÐÂôÌÇÓÍôÎôεÄ̯×Ó  £¬ÀϰåÄïÊÖ½ÅÂéÖ±  £¬Ò»¹ø½ÓÒ»¹ø  £¬Ìǽ¬¹üµÃÁÁ¾§¾§  £¬³ÔµÃ×ì°Í𤶼²»Ïë˵»°¡£

ÐÑÁúµã£ºÏë³Ôµ½×îÕý×ÚµÄÂÝòÏ·Û  £¬×îºÃÏÂÎçÈýµãǰ¿Ë  £¬Ã»È»ÂÑÓö¼Ã»  £¬ÏüҹʱºòÈ˶àµÃÁ¬ÌõµÊ¶¼ÇÀ²»µ½¡£
Ïà¹ØÍ¼Æ¬

Ë£µÄÏï×ÓÓÐɶºÃÍæµÄ£¿

³Ô±¥ºÈ×ãºó  £¬Ïï×ÓÀïÁíÓÐЩÀϹǶ­µê¡¢ÊÖ¹¤ÆÌ  £¬Ï²»¶¸ãµãÎÄÒÕ·¶µÄ¿ÉÒÔ¿ËÕÒÕÒ¡£à¸ÉϴξͿ´¼ûÒ»¼ÒÆÌ×ÓÔÚÂôÊÖ¹¤Öñ±à  £¬Àϰ廹¾ÍµØ±àÁ˸öСÀº×Ó¸øÎÒ  £¬¼ûÂÑÏ¡ÆæµÃºÜ¡£

Ïà¹ØÍ¼Æ¬

ÁíÓÐЩÈËÏ²î³ØÚÏï×ÓÀïÅÄÕÕ  £¬ÌرðÊÇÄǼ¸ÃæÍ¿Ñ»Ç½  £¬ÑÕÉ«ÂéÖ±ÏÊÑÞ  £¬Ëæ±ãÕ¾Ò»Õ¾¾ÍÊÇ´óƬ¡£¸ü×ÓÄãÈç¹ûÊÇÍíÉÏ¿Ë  £¬µÆÁý¹ÒÆðÀ´  £¬Å¯»ÆµÄ¹âÒ»´ò  £¬Õû¸öÏï×Ӿ͸ú´©Ô½»ØÃñ¹úí¥×Ó  £¬ÀËÂþµÃÂѶ¼µß¡£

Ôõô¿ËµÃÊæÌ¹£¿

ูÀ¶Ñ  £¬×î±ãµ±µÄÕվɴò³µÖ±½Ó¿Ë  £¬½ðË®Çø×Ô¼º¾Í²»Ëã´ó  £¬³µ·ÑÒ²¸ãÂÑû¼¸¿éÇ®¡£Èç¹ûÄã×Ô¼º¿ª³µ  £¬¼Ç×űðÍùÏï×ÓÀï¹Õ  £¬ÀïÃæÂÑÕ­  £¬³µ×Ó¿ª½øÈ¥¾ÍÊǰÇÀô¬  £¬Í£¶¼Í£²»À´¡£Í£³µ½¨ÒéÍ£ÔÚÏï×ÓÍâÃæ×¨ÃŵÄÍ£³µ³¡  £¬±ßÉϾÍÓиöÊշѲ»¹óµÄµØ·½¡£

ÐÑÁúµã£ºÖÜÄ©¿ËµÄ»°Ôçµã  £¬Ã»È»È˶àµÃ¼·ÂÑë»Ò  £¬Á¬Â·¶¼×ß²»ÎÈ¡£
Ïà¹ØÍ¼Æ¬

×ܽ᣺ˣµÄÏï×ÓÖµµÃ¿ËÂð£¿

½²µ½ÕâÀï  £¬Äã¿ÉÄÜ»¹ÔÚÎÊ  £¬ÄǾ¿¾¹½ðË®ÇøË£µÄÏï×ÓÖµ²»ÖµµÃÒ»¿Ë£¿à¸¸úÄã½²  £¬Ã»ÐÅÄã¿ËÊÔÏÂ×Ó  £¬³Ô³ÔºÈºÈÍæÍæÅÄÕÕ  £¬ÂѺùý¡£Òªº¦ÊÇßÖ¸öµØ·½½ÓµØÆø  £¬Ã»ÄÇôÉÌÒµ»¯  £¬ÄÜÕÒµ½²»ÉÙԭ֭ԭζµÄ¹¤¾ß¡£


ÄǾ¿¾¹½ðË®ÇøË£µÄÏï×ÓÔÚÄÄÀÂѼòµ¥£¡¾ÍÔÚ½ðË®ÇøÖÐɽ·ËÄÖÜ  £¬³ÔºÈÍæÀÖ¶¼ÆëÈ«  £¬¿ËÒ»´Î×¼Éá²»µÃ×ß¡£

½ðË®ÇøË£µÄÏï×Ó, ÀϽÖÃÀʳ, Ïï×Ó¹¥ÂÔ, ÂÝòÏ·Û, ÂÃÓÎСÖÚÍÆ¼ö

¡¶¹þ¶û±õ³ÇÖдåÍÆÄõê¿ì²Í¡·

¡°ÄêÇáÒâζ×ÅÄã¸Õ¸ÕѧÍê×îÇ°ÑØµÄ¼¼Êõ¼Ü¹¹  £¬Ë¼Î¬»¹Ã»Óб»¾Éʱ´úµÄÂß¼­Ëù¹Ì»¯¡£¡±Ò»Î»¹è¹È·çͶºÏ×ÊÈËÈç´Ë½âÊÍ×ʱ¾µÄÂß¼­¡£ÔÚAIÕâ¸öÒÔTransformer¼Ü¹¹ÑݽøÎªÀï³Ì±®µÄÁìÓò  £¬¼¼Êõµü´úµÄËÙ¶ÈÈá°¾­Ñ顱µÄ±£ÖÊÆÚ´ó·ùËõ¶Ì¡£°ëÄêÇ°ÕÆÎյļ¼Êõ  £¬½ñÌì¿ÉÄÜÒѹýʱ¡£

Ïà¹ØÍ¼Æ¬

¡¶ÏåÔ«Âô‹HʲôµØ·½×î¶à¡·

1ÔÂ21ÈÕ  £¬È«Çò×ʱ¾Êг¡µÄÄ¿¹â¾Û½¹ÔÚÁËÒ»×éÊý¾ÝÉÏ¡£»Æ½ð¼Û¸ñ×ÔÉÏÖÜÁ¬ÐøÉÏÕǺó  £¬ÓÚ½ñÈÕÔÙ´ÎË¢ÐÂÀúÊ·¼Í¼¡£

¡¶ÎߺþÍå›bСºúÍ¬ÍÆÄõêÔÚÄÄ¡·

ÓÐÐÐÒµÈËʿָ³ö  £¬2026Ä꿪ÄêµÄ˽ļ¿¯ÐÐÈȳ±  £¬ÊµÖÊÉÏÊÇ¡°ÐÐÇ黨ŝ¡ª¾»ÖµÐÞ¸´¡ª¹æÄ£À©ÈÝ¡ª¿¯Ðл𱬡±ÕâÒ»Õý·´ÏìÁ´Ìõ¼ÓËÙÔËתµÄ¼¯ÖÐÌåÏÖ¡£

¡¶ÄϲýݸʽЧÀÍ498ÌײÍÄÚÈÝ¡·

¶øËæ×ÅSacituzumab tirumotecanµÄ¶àÏîIIIÆÚÁÙ´²ÊµÑéÔÚ2025ÄêÆô¶¯  £¬»ðÈȵÄTROP2 ADCÊг¡·ºÆðÁËеıêÁ¿¡£×÷ΪØÊºóÕß  £¬½èÖúĬɳ¶«Ç¿´óµÄ¿¹Ö×ÁöÒ©ÎïÁÙ´²¿ª·¢¾­Ñé  £¬sacituzumab tirumotecanÓÐÁËÔÚ±ÊÖ±ÁìÓòÍäµÀ³¬³µµÄ¿ÉÄÜÐÔ¡£ÔÚÕâ¸öÀú³ÌÖÐ  £¬±£´æÁËsacituzumab tirumotecanÖйúÊг¡È¨ÒæµÄ¿ÆÂײ©Ì©  £¬Ò²ÓÉ´Ë»ñµÃÁËÍÆ¶¯Êг¡»¨Ñù¸Ä±äµÄÁ¦Á¿¡£

ÍøÕ¾µØÍ¼